Korean Circ J.  2025 Feb;55(2):132-133. 10.4070/kcj.2024.0361.

Is Rivaroxaban Safe in Patients With Renal Dysfunction?

• Jin ES

• KMID: 2565418
• DOI: http://doi.org/10.4070/kcj.2024.0361

Reference

1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891. PMID: 21830957.

2. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45:3314–3414. PMID: 39210723.

3. Oh IY, Choi KJ, Lee CH, et al. A real-world, prospective, observational study of rivaroxaban on prevention of stroke and non-central nervous systemic embolism in renally impaired Korean patients with non-valvular atrial fibrillation: XARENAL. Korean Circ J. 2025; 55:121–131. PMID: 39601397.

4. Yu HT, Yang PS, Kim TH, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke. 2018; 49:2421–2429. PMID: 30355093.

5. Shin JI, Secora A, Alexander GC, et al. Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. Clin J Am Soc Nephrol. 2018; 13:1144–1152. PMID: 30002224.

6. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014; 129:961–970. PMID: 24323795.